Yael Cohen - Vascular Biogenics Vice President - Clinical Development

VBLTDelisted Stock  USD 0.28  0.01  3.45%   

President

Dr. Yael Cohen serves as Vice President Clinical Development at Vascular Biogenics Ltd since 2008. Her work experience includes various roles at Gamida Cell Ltd, Merck Co. and Merck Research Labs . Dr. Cohen holds a Doctorate of Medicine degree from the Sackler Medical School at Tel Aviv University and has completed her residency in Internal Medicine at the Chaim Sheba Medical Center at Tel Hashomer, Israel, and a fellowship in Hematology at the Rabin Medical Center, Petach Tikva, Israel. Dr. Cohen is a Senior Physician at the Hematology Department at the Sourasky Medical Center, Tel Aviv, Israel. since 2008.
Age 60
Tenure 16 years
Phone972 8 993 5000
Webhttps://www.vblrx.com

Vascular Biogenics Management Efficiency

The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.
Vascular Biogenics currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vascular Biogenics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 5 records

PRESIDENT Age

Robert LisickiZura Bio Limited
56
Srinivas SubramanianAvenue Therapeutics
53
James DohertyAcumen Pharmaceuticals
56
Erin MDTerns Pharmaceuticals
53
Kelly CarranzaAcumen Pharmaceuticals
N/A
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Vascular Biogenics (VBLT) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

Vascular Biogenics Leadership Team

Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Samuel Backenroth, Chief Officer
Naamit Sher, VP of Devel. and Regulatory
Yael Cohen, Vice President - Clinical Development
Erez MBA, Sr Operations
Eyal Breitbart, Vice President Research
Deborah Scott, Managing Communications
Pr MD, CEO Director
Advocate Horn, G Counsel
Tami MD, VP Devel

Vascular Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Vascular Biogenics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vascular Biogenics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vascular Biogenics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Vascular Stock

  0.61EC Ecopetrol SA ADRPairCorr

Moving against Vascular Stock

  0.81INTC Intel Sell-off TrendPairCorr
  0.8CSCO Cisco Systems Aggressive PushPairCorr
  0.76MCD McDonalds Financial Report 25th of July 2024 PairCorr
  0.73TRV The Travelers Companies Financial Report 18th of July 2024 PairCorr
  0.66KEP Korea Electric PowerPairCorr
The ability to find closely correlated positions to Vascular Biogenics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vascular Biogenics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vascular Biogenics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vascular Biogenics to buy it.
The correlation of Vascular Biogenics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vascular Biogenics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vascular Biogenics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vascular Biogenics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.